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http://www.joppp.org/content/6/1/6RESEARCH Open AccessAccess to antibiotics in New Delhi, India:
implications for antibiotic policy
Anita Kotwani1* and Kathleen Holloway2Abstract
Objective: The present survey was conducted to investigate the price and availability of a basket of 24 essential
antibiotics and eight high-end antibiotics at various levels of health care in public and private sector in National
Capital Territory of Delhi, India using standardized WHO/HAI methodology.
Methods: Data on procurement price and availability was collected from three public healthcare providers in the
state: the federal (central) government, state government and Municipal Corporation of Delhi (MCD). Overall a total
of 83 public facilities, 68 primary care, 10 secondary cares and 5 tertiary care facilities were surveyed. Data was also
collected from private retail (n = 40) and chain pharmacies (n = 40) of a leading corporate house. Prices were
compared to an international reference price (expressed as median price ratio-MPR).
Results: Public sector: Delhi state government has its essential medicine list (Delhi state EML) and was using Delhi
state EML 2007 for procurement; the other two agencies had their own procurement list. All the antibiotics
procured including second and third generation antibiotics except for injections were available at primary care
facilities. Antibiotic available were on the basis of supply rather than rationality or the Delhi state EML and none
was 100% available. There was sub-optimal availability of some essential antibiotics while other non-essential ones
were freely available. Availability of antibiotics at tertiary care facilities was also sub-optimal. Private sector:
Availability of antibiotics was good. For most of the antibiotics the most expensive and popular trade names were
often available. High-end antibiotics, meropenam, gemifloxacin, and moxifloxacin were commonly available. In retail
pharmacies some newer generation non-essential antibiotics like gemifloxacin were priced lower than the
highest-priced generic of amoxicillin + clavulanic acid, azithromycin, and cefuroxime aexitl.
Conclusions: Inappropriate availability and pricing of newer generation antibiotics, which may currently be bought
without prescription, is likely to lead to their over-use and increased resistance. All providers should follow the EML
of whichever of the three concerned Delhi public sector agencies that it is under and these EMLs should follow the
essential medicine concept. The Indian regulatory authorities need to consider urgently, drug schedules and pricing
policies that will curtail inappropriate access to new generation antibiotics.
Keywords: Access, Antibiotics, Antibiotic availability, Antibiotic price, Primary care, Public health sector, Private retail
pharmacies, Procurement priceIntroduction
Antimicrobial resistance (AMR) is rapidly increasing
globally, therefore suitable policy and actions are ur-
gently needed to combat AMR [1]. The widely held con-
sensus for the rapid increase in development of AMR is
over-prescribing and inappropriate use of antibiotics
[2,3]. This consensus leads in turn to the need for having* Correspondence: anitakotwani@gmail.com
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distribution, and reproduction in any mediuman antibiotic policy that should ensure critical selection
and appropriate use of antibiotics [4]. Since health sys-
tems and prescribing behavior are varied and complex, a
nationally or locally coordinated antibiotic policy, con-
textualized to the particular country/region, will be
needed to have any substantial impact on appropriate
antibiotic use.
The first step in combating inappropriate use of anti-
biotics is to measure access and use of antibiotic in
order to quantify the scale of the problem and to have ad Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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intervention. In a number of developed countries, exten-
sive surveillance programs have been developed to study
patterns of antibiotic use and guidelines for antibiotic
use [5-7]. However, the ability to undertake such surveil-
lance is lacking in resource-constrained settings. The
problem of AMR, appropriate availability and inappro-
priate use of antibiotics has received relatively little rec-
ognition in developing countries [8]. Recently, a few
collaborative studies were conducted in India for devel-
oping a validated methodology for measuring consump-
tion and antibiotic use in the community and hospital
[8-10]. Overprescribing, misuse of antibiotics and low
adherence to treatment guidelines were seen in both
public and private settings [10-13]. However, there is no
literature available in India on access, availability and
price of various antibiotics at public and private retail
pharmacies. Hence, the present reported survey was
undertaken (July-October 2011) with the objective to
study to measure the access of various antibiotics in
public and private sectors in New Delhi using a stan-
dardized methodology of World Health Organization
and Health Action International (WHO/HAI) [14]. The
survey was undertaken with the ultimate objective to
move towards enabling an antibiotic policy that will en-
courage availability of appropriate antibiotics (and not
inappropriate ones) and hence their rational use at dif-
ferent level of healthcare.
Methods
State background
Delhi, the capital of India is known as the National Cap-
ital Territory of Delhi (NCT Delhi).
Three main public sector health care providers in
NCT Delhi are: the Central (federal) Government
under the Ministry of Health and Family Welfare
(MoH&FW), the Directorate of Health Services (DHS)
in the Government of NCT (GNCT) Delhi and another
public sector provider in Delhi city – the Municipal
Corporation of Delhi (MCD). All citizens can visit and
avail the free services in the facilities of the three pub-
lic healthcare providers. All these public sectors have
their own procurement systems and essential or pro-
curement list of medicines.
In the private sector, recently, chain pharmacies have
entered the Indian retail sector. Therefore, both types of
retail pharmacies were included in the survey, the trad-
itional private retail pharmacies and the chain pharma-
cies of a leading corporate house.
Sampling
This survey followed the WHO/HAI methodology [14] and
was conducted in all eight districts of Delhi and surveyed
five facilities in each district covering the entire Delhi state.Public sector
Central procurement prices were collected from all the
three centralized public sector procurement agencies/de-
partment of healthcare providers. Tertiary care facilities
under central government (CG) also undertake inde-
pendent medicine procurement to augment the supply
from the central government procurement agency. Pro-
curement prices were also collected from these tertiary
care facilities; namely, Ram Manohar Lohia (RML) Hos-
pital and Safdurjung Hospital (SH) which have common
pooled procurement (labeled as CG1) and Lady Har-
dinge Medical College (LH) which has independent pro-
curement (labeled as CG2).
Medicines are provided for free in all public facilities
hence only antibiotic availability was collected from the
various public facilities. For each district one secondary
care hospital and four primary health care (dispensaries)
were randomly selected. In one of the districts a tertiary
care instead of secondary care hospital was enrolled.
Overall a total of 83 facilities (40 facilities under GNCT,
Delhi, 40 under MCD and 3 tertiary care facilities of
CG) were surveyed (Table 1).
Private sector
The private sector samples were identified by selecting
one retail pharmacy outlet in each sector that is geo-
graphically closest to each public outlet. In each
district five retail pharmacies and five retail chain
pharmacies were included. Thus a total of 80 facilities
were surveyed.
Antibiotics surveyed
The WHO/HAI methodology identifies a basket of 30
core medicines – 14 essential medicines from global
burden of diseases and 16 specific for a particular region,
South East Asia. Of these 30 medicines, seven are antibi-
otics in different dosage forms (Table 2). To these core
seven antibiotics, a supplementary list of 17 antibiotics
from various classes were added as mentioned in Table 3
on the basis of their inclusion in Delhi State essential
medicine list (EML). Also, a further eight high-end anti-
biotics (listed in the footnote of Table 3) were surveyed
in secondary care and tertiary care public facilities and
private sector pharmacies.
As per the WHO/HAI methodology [14] data was col-
lected for both the originator brand, and the lowest-
priced generic equivalent found at each medicine outlet.
Until 2005, the Indian regulatory system recognized
process patents not product patent and therefore all
medicines that are manufactured in India are generic
versions. However, all products carry a brand (trade)
name [15]. Originators brands (OBs) in India do not have
any additional recognition as originator brand. Often OBs
are not available but the same molecules manufactured by
Table 1 Number of facilities in each survey area under public and private sector
S.No Survey
area
Public sector* Private Sector#










1 Central 5 2 5 5 5
2 South 5 1 5 5 5
3 East 5 5 5 5
4 North 5 5 5 5
5 North East 5 5 5 5
6 North West 5 5 5 5
7 South West 5 5 5 5
8 West 5 5 5 5
Total 40 3 40 40 40
Grand total 83 80
*For public sector one version of each medicine, the lowest-priced generic (LPG) were collected for both price and availability as public sector procure only one
generic version of each medicine.
#For private sector, Seven core antibiotics were surveyed in three versions, Originator brand (OB), Highest-priced generic (HPG) and Lowest-priced generic (LPG);
Seventeen supplementary antibiotics and eight high end antibiotics were surveyed in two versions, HPG and LPG.







1 Amoxicillin + Clavulanic
acid
500 g + 125 mg cap/tab
2 Amoxicillin 250 250 mg Tab/cap





4 Ampicillin Suspension 125 mg/5 ml mililitre




7 Cefixime 200 mg Tab/cap
8 Cefuroxime axetil 250 mg Tab/cap
9 Cefuroxime Suspension 125 mg/5 ml mililitre
10 Cephalexin 500 mg Tab/cap
11 Cephalexin Syrup 250 mg/5 ml mililitre
12 Erythromycin powder for 125 mg/5 ml mililitre
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nerics, are available. Therefore, for this survey, in addition
to originator brand and lowest-priced generic (LPG) a
third version, highest-priced generic (HPG) was added to
find out the price and availability of seven core antibiotics
available at each facility. For seventeen supplementary an-
tibiotics and eight high-end antibiotics, two versions,
highest-priced and lowest-priced generics were surveyed
and found at each private facility (Table 1, 2, and 3).
Since the public sector has only one version of each
medicine, only the lowest-priced generic (LPG) were col-
lected for both price and availability.
Data collection, entry and analysis
Trained data collectors visited enrolled facilities with a
standardized form and recorded the price and availability
of each antibiotic medicine. For public sector, procure-
ment price was collected from three central agencies -








1 Amoxicillin 500 mg cap/tab
2 Amoxicillin suspension 25 mg/ml millilitre
3 Ceftriaxone injection 1 g/vial vial
4 Ciprofloxacin 500 mg cap/tab
5 Co-trimoxazole
suspension
8 + 40 mg/ml mililitre
6 Doxycycline 100 mg cap/tab
7 Gentamicin eye drops 0.3% millilitre
suspension
13 Erythromycin Stearate 250 mg Tab/cap
14 Gentamicin injection 40 mg/ml inj
15 Norfloxacin 400 mg Tab/cap
16 Ofloxacin 200 mg Tab/cap
17 Roxithromycin 50 mg Tab/cap
Additional list of eight high-end antibiotics surveyed in hospitals and
private pharmacies.
1. Meropenem 500 mg inj.
2. Imipenem + cilastatin 500 mg + 500 mg inj.
3. Colistin inj 1,000,000 units/vial.
4. Vancomycin 500 mg inj.
5. Ceftazidime 1 g vial.
6. Cefepime 1 g inj.
7. Gemifloxacin 320 mg.
8. Moxifloxacin 400 mg.
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MCD; and Medical Stores Organization (MSO), procure-
ment department of CG. Procurement price was also col-
lected from two decentralized sites of central government
hospitals – CG1 (RML/SH) and CG2 (LH).
Medicine unit prices were entered into Excel spread-
sheets with double entry, auto-checking, and automated
analysis feature of the workbook developed by WHO/
HAI [14]. To facilitate international comparisons, anti-
biotic prices are expressed as median price ratio (MPR)
[16]. The MPR is the local median unit price of a medi-
cine in comparison with the median unit price found in
the Management Sciences for Health (MSH) Price Indi-
cator Guide, 2010 [17].
Ethical approval
Ethical approval of the study was obtained from Vallabhbhai
Patel Chest Institute, University of Delhi, India. Permis-
sion for data collection was obtained from HealthTable 4 Median price ratios (MPRs) of surveyed antibiotics in
Antibiotic no. Medicine name
1 Amoxicillin + Clavulanic acid 500 mg + 125 mg cap/tab
2 Amoxicillin 500 mg cap/tab
3 Amoxicillin 250 mg cap/tab
4 Amoxicillin suspension 25 mg/ml
5 Amoxicillin + Clavulanic acid Syrup 200 mg + 28.5 mg/5 m
6 Ampicillin Suspension 125 mg/5 ml
7 Azithromycin 500 mg cap/tab
8 Benzathine Penicillin Powder 2.4MU/vial
9 Cefixime 200 mg cap/tab
10 Ceftriaxone injection 1 g/vial
11 Cefuroxime axetil 250 mg cap/tab
12 Cefuroxime Suspension 125 mg/5 ml
13 Cephalexin 500 mg cap/tab
14 Cephalexin Syrup 250 mg/5 ml
15 Ciprofloxacin 500 mg cap/tab
16 Co-trimoxazole suspension 8 + 40 mg/ml
17 Doxycycline 100 mg cap/tab
18 Erythromycin powder for suspension 125 mg/5 ml
19 Erythromycin Stearate 250 mg cap/tab
20 Gentamicin eye drops 0.3%
21 Gentamicin injection 40 mg/ml
22 Norfloxacin 400 mg cap/tab
23 Ofloxacin 200 mg cap/tab
24 Roxithromycin 50 mg cap/tab
MSO Medical store organization, the procurement agency for central government h
done by two tertiary care hospitals of central government, CG2 decentralized procu
procurement agency for Government of National Capital Territory of Delhi.
* MSH price is not available therefore MRP can not be calculated.Department, Directorate Health Services (DHS) of Gov-
ernment of NCT Delhi, Municipal Corporation of Delhi,





The median MPR of each antibiotic surveyed, whether
it is on the Delhi state EML and which procurement
agencies procured these antibiotics are shown in Table 4.
The 2007 Delhi sate EML was used for purchase of
medicines for Delhi state run facilities at the time of the
survey in 2011 [18]. Out of 24 antibiotics surveyed, 20
antibiotics were on Delhi state EML used by the CPA,
the GNCT, Delhi procurement agency, which was pro-
curing all antibiotics on the list except benzathine pe-
nicillin. The other two public sector procurement
agencies did not have their own EML but had their listvarious public sector procurement agencies in Delhi
Delhi state EML 2007 Median MPR Procurement agencies
No 0.91 MCD, CG1,CG2
Yes 1.22 MCD, CG2,CPA
Yes 1.11 MCD, CG1,CG2, CPA
Yes 1.04 MCD,CG1,CG2,CPA





Yes 0.50 MSO, MCD, CG1,CG2, CPA














ospitals, MCD Municipal corporation of Delhi, CG1 decentralized procurement
rement done by single tertiary care hospital of central government, CPA the
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tute committee.
A few antibiotics, e.g., azithromycin, ceftriaxone injection,
erythromycin, gentamicin eye drops, gentamicin injection,
and roxithromycin were found to have large variation in
procurement price by different agencies (Table 5). Usually
the highest procurement price for these medicines was for
the tertiary care facilities (CG2 and CG1) doing independ-
ent procurement and the least price was for CPA-GNCT,
Delhi which manages pooled procurement for all the facil-
ities under the Delhi state government.
Availability of surveyed antibiotics
Table 6 depicts the availability of surveyed antibiotics
in primary care (dispensaries), secondary care hospitals
and tertiary care level of hospital under Delhi state gov-
ernment, (GNCT, Delhi) and under Municipal Corpor-
ation of Delhi (MCD). Three antibiotics which were
not in Delhi State EML were found: amoxicillin +
clavulanic acid tablet was available at all three levels of
health care of Delhi State and MCD and 2 out of three
tertiary care facilities of Central Government (CG).
Amoxicillin + clavulanic acid syrup and cefixime was
available at primary and secondary care facilities of
GNCT, Delhi and MCD and only at one tertiary care fa-
cility of MCD.
Antibiotics with more than 80% availability at GNCT,
Delhi-run primary care were: amoxicillin500 mg and
norfloxacin tablets. Antibiotics with more than 80%
availability at MCD run primary care were none and at
secondary care were ciprofloxacin and doxycycline. The
availability of some essential antibiotics e.g. ampicillin
suspension, erythromycin suspension and tablets for
primary care were sub-optimal, particularly in MCD.
Table 7 shows availability of antibiotics in tertiary
care facilities of Central Government. Four antibiotics
amoxicillin250 mg, ciprofloxacin, erythromycin stear-
ate, and norfloxacin for OPD patients and two injec-
tions ceftriaxone and gentamicin were available in allTable 5 Variation in unit procurement price in local currency
agencies in New Delhi
Antibiotic name MSO(central government MCD CG1
Azithromycin cap/tab No rate available 6.31 No
Ceftriaxone injection 14.99 18.28 16.4
Erythromycin Stearate 1.43 1.32 2.04
cap/tab
Gentamicin eye drops No rate available 0.61 0.81
Gentamicin injection No rate available 1.40 1.53
Roxithromycin cap/tab 1.04 1.29 No
MSO Medical store organization, the procurement agency for central government h
done by two tertiary care hospitals of central government, CG2 decentralized procu
procurement agency for Government of National Capital Territory of Delhi, INR Indithree tertiary care facilities. By contrast some essential
antibiotics e.g. amoxicillin suspension, doxycycline and
cephalexin were poorly available.
Private sector
Price-to-patient
The median MPR for all versions, minimum and max-
imum MPR found at retail pharmacies and median unit
price in local currency is shown in Table 8. Findings
were similar at retail chain pharmacies, except for a few
antibiotics, like amoxicillin suspension, cephalexin syrup,
and gentamicin eye drops whose median MPRs were
found to be little less and for few antibiotics, like cipro-
floxacin, doxycycline, median MPRs a little more than
the median MPRs found at private retail pharmacies.
Price variation between highest and lowest generic
For certain medicines huge price variation was observed
for highest-priced and lowest-priced generic available at
the surveyed retail facilities. The mean MPR of highest
and lowest-priced generic is shown in Figure 1 and the
highest variation of 5.1 times was seen for doxycycline,
followed by amoxicillin + clavulanic acid tablet (3.3 times).
Overall availability
Except for two antibiotics all other antibiotics were avail-
able in the private sector (Table 8). If only one version
of the medicine (apart from originator for seven core
medicines) was available then that medicine’s name and
price became the lowest-priced generic available. Results
were similar at chain pharmacies although the availabil-
ity of certain antibiotics like cephalexin was more at
chain pharmacies.
Antibiotics with very poor availability
The two antibiotics that had very poor or no availability
{0.0%-2.5% in any version (OB or generic)}, were, ampi-
cillin suspension and benzathine penicillin powder. Both
the antibiotics are included in the Delhi state EML.(INR) of few antibiotics by different procurement
CG2 CPA(Delhi state government)





rate available No rate available 0.74
ospitals, MCD Municipal corporation of Delhi, CG1 decentralized procurement
rement done by single tertiary care hospital of central government, CPA the
an Rupees, Local currency.
Table 6 Availability of surveyed antibiotics in primary, secondary and tertiary care facilities of two public sectors in
Delhi, India
Antibiotic name GNCT Delhi MCD
Pr. care Second care Tertiary care Pr. care Second care Tertiary care
(n = 32) (n = 7) (n = 1) (n = 36) (n = 3) (n = 1)
1. amoxicillin 250 + clavulanic acid$ 21.9% 42.9% Available 52.8% 66.7% Available
2. Amoxicillin 250# 71.9% 57.1% Available 19.4% 33.3% N.A
3. Amoxicillin 500# 81.3% 85.7% Available 30.6% 66.7% Available
4. Amoxicillin suspension# 62.5% 100.0% Available 5.6% 0.0% N.A
5. Amoxicillin + clavulanic acid 31.3% 14.3% N.A 58.3% 66.7% Available
Syrup$
6. Ampicillin suspension# 25.0% 0.0% N.A 2.8% 0.0% N.A
7. Azithromycin@ 0.0% 14.3% Available 2.8% 0.0% N.A
8. Benzathine Penicillin Powder# 0.0% 0.0% N.A 0.0% 0.0% N.A
9. Cefixime$ 21.9% 14.3% N.A 25.0% 66.7% Available
10. Ceftriaxone injection@* 0.0% 57.1% Available 0.0% 0.0% N.A
11. Cefuroxime axetil@* 43.8% 71.4% N.A 47.2% 66.7% N.A
12. Cefuroxime suspension@* 0.0% 28.6% N.A 0.0% 0.0% N.A
13.Cephalexin#* 43.8% 71.4% N.A 19.4% 33.3% N.A
14. Cephalexin syrup#* 53.1% 14.3% Available 8.3% 0.0% N.A
15. Ciprofloxacin# 37.5% 100.0% Available 72.2% 100.0% Available
16. Co-trimoxazole suspension# 56.3% 85.7% Available 2.8% 0.0% N.A
17. Doxycycline# 50.0% 71.4% Available 69.4% 100.0% Available
18. Erythromycin powder for suspension# 40.6% 42.9% Available 0.0% 0.0% N.A
19. Erythromycin stearate# 43.8% 57.1% Available 0.0% 0.0% N.A
20. Gentamicin eye drops@ 59.4% 71.4% Available 11.1% 33.3% N.A
21. Gentamicin injection@ 3.1% 28.6% Available 0.0% 0.0% N.A
22. Norfloxacin# 84.4% 85.7% Available 2.8% 0.0% N.A
23. Ofloxacin@ 37.5% 71.4% Available 47.2% 66.7% Available
24. Roxithromycin# 40.6% 71.4% N.A 8.3% 0.0% N.A
$Not in the Delhi State EML 2007 for Hospitals and dispensaries.
# For primary care (dispensaries) Delhi State EML2007.
#* Reserve antibiotics for restricted use in primary care.
@Antibiotics for hospital; these are in addition to antibiotics for primary care facilities.
* Reserve antibiotics to be used only in case of significant resistance to other antibiotics.
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A few antibiotics were generally available at both retail
pharmacies and chain pharmacies with only one trade
name which was usually the most popular brand name.
These antibiotics were: ceftriaxone injection, cefuroxime
suspension, cephalexin, cephalexin syrup, co-trimoxazole
suspension, erythromycin stearate, gentamicin eye drops,
gentamicin injection, norfloxacin, and roxithromycin.
Price variations for few antibiotics in public and
private sector
We expect medicines to be more costly in private retail
sector than the public procurement price. For few antibi-
otics the price variations was high as could be seen in
Tables 4 and 8. It was found that median MPR of lowest-priced generic (LPG) in private sector for cefuroxime sus-
pension and cephalexin syrup were seven times; amoxicil-
lin500 mg, amoxicillin250 mg, cefuroxime were five times;
and for cephalexin 6.5 times higher in the private retail
sector as compared to median MPR for public procure-
ment price.Price and availability of high-end antibiotics surveyed
Availability and price of surveyed high-end antibiotics at
tertiary and secondary care facilities of public sector
All five procurement agencies were procuring or had
fixed the rates for vancomycin and meropenam injection
(Table 9). For the two oral antibiotics, gemifloxacin and
moxifloxacin tablets procurement price was available
Table 7 Availability of surveyed antibiotics in facilities surveyed in three tertiary care facilities of federal government
in Delhi, India
Medicines CGH(n = 3) LH RML SH
1. Amoxicillin + clavulanic acid 66.7% Available N.A Available
2. Amoxicillin 250 100.0% Available Available Available
3. Amoxicillin 500 33.3% Available N.A N.A
4. Amoxicillin suspension 33.3% Available N.A N.A
5. Amoxicillin + clavulanic acid Syrup N.A N.A N.A N.A
6. Ampicillin suspension N.A N.A N.A N.A
7. Azithromycin 33.3% Available N.A N.A
8. Benzathine Penicillin Powder 66.7% N.A Available Available
9. Cefixime N.A N.A N.A N.A
10. Ceftriaxone injection 100.0% Available Available Available
11. Cefuroxime axetil N.A N.A N.A N.A
12. Cefuroxime suspension N.A N.A N.A N.A
13. Cephalexin 33.3% N.A Available N.A
14. Cephalexin syrup 33.3% Available N.A N.A
15. Ciprofloxacin 100.0% Available Available Available
16. Co-trimoxazole suspension 66.7% Available Available N.A
17. Doxycycline 33.3% Available N.A N.A
18. Erythromycin powder for suspension 66.7% Available Available N.A
19. Erythromycin stearate 100.0% Available Available Available
20. Gentamicin eye drops 66.7% Available N.A Available
21. Gentamicin injection 100.0% Available Available Available
22. Norfloxacin 100.0% Available Available Available
23. Ofloxacin 66.7% Available Available N.A
24. Roxithromycin N.A N.A N.A N.A
CGH Central Government Hospitals.
LH Lady Hardinge Medical College & Associated Hospitals.
RML Ram Manohar Lohia Hospital.
SH Safdarjung Hospital.
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hospitals during the survey. Colistin injection was not
procured by any agency. All five tertiary care hospitals
had one or more surveyed antibiotics (Table 10). Out of
the ten secondary care hospitals, two of Delhi govern-
ment and one from MCD had no surveyed high-end
antibiotics. The availability pattern indicates that the
most common high-end antibiotic available in the hospi-
tals is ceftazidime injection followed by meropenam and
vancomycin injection.
Availability and price of surveyed high-end antibi-
otics in private sector At private retail pharmacies the
availability of high-end antibiotics was poor (Table 10).
Still meropenam injection was available at 13 pharma-
cies and gemifloxacin and moxiflocin tablets were avail-
able at 15 and 16 pharmacies out of 40 surveyed retail
pharmacies. Compared to retail pharmacies, availability
of high-end antibiotics was better at chain pharmaciesmoxifloxacin, gemifloxacin, and meropenam injection
being available at 72.5%, 50.0%, and 52.5% of these phar-
macies. Prices of these antibiotics were similar to the
prices available at retail pharmacies, except that two ver-
sions (trade names) of moxifloxacin were available at five
chain pharmacies.
Discussion
This survey has provided a snap shot of availability of
various antibiotics in the community in Delhi in both
the public and private sectors. The methodology used
for the survey is a standardized methodology for meas-
uring access to essential medicines. Results from these
WHO/HAI medicine price surveys are used for situation
analysis and to plan interventions to improve access to
essential medicines for global population [19-21].
Despite the strengths, the WHO/HAI methodology
has a few limitations. First, availability and price are de-
termined for a specific list of survey medicines, and do
Table 8 Median price ratio, median unit price in local currency and availability of surveyed antibiotics at private retail
pharmacies




Min Max % of facilities with
antibiotic
Median unit price in
INR
1 Amoxicillin + Clavulanic acid Highest Price 4.83 0.48 4.83 95.0% 40.17
Amoxiciilin + Clavulanic acid Lowest Price 1.44 0.50 4.83 100.0% 11.99
2 Amoxicillin Brand N.A N.A N.A 0.0% N.A
Amoxicillin Highest Price 7.45 7.21 7.46 95.0% 9.65
Amoxicillin Lowest Price 7.21 5.05 7.45 97.5% 9.33
3 Amoxicillin 250 Highest Price 7.73 7.20 7.73 72.5% 5.90
Amoxicillin 250 Lowest Price 5.50 4.28 7.73 92.5% 4.20
4 Amoxicillin suspension Brand N.A N.A N.A 0.0% N.A
Amoxicillin suspension Highest Price 7.02 3.64 7.02 57.5% 1.41
Amoxicillin suspension Lowest Price 4.55 3.28 7.04 95.0% 0.91
5 Amoxicillin + Clavulanic acid
Syrup
Highest Price * 62.5% 3.64
Amoxicillin + Clavulanic acid
Syrup
Lowest Price * 92.5% 1.58
6 Ampicillin Suspension Highest Price # 2.5%
Ampicillin Suspension Lowest Price # 2.5%
7 Azithromycin Highest Price 2.06 1.42 2.16 95.0% 30.83
Azithromycin Lowest Price 1.57 1.14 2.06 100.0% 23.50
8 Benzathine Penicillin Powder Highest Price - - - 0.0% -
Benzathine Penicillin Powder Lowest Price - - - 0.0% -
9 Cefixime Highest Price 2.53 1.74 2.55 80.0% 19.81
Cefixime Lowest Price 1.26 0.87 2.56 97.5% 9.90
10 Ceftriaxone injection Brand N.A N.A N.A 0.0% N.A
Ceftriaxone injection Highest Price # 2.5%
Ceftriaxone injection Lowest Price 2.24 1.95 2.24 47.5% 69.00
11 Cefuroxime axetil Highest Price 5.73 3.59 5.73 55.0% 43.10
Cefuroxime axetil Lowest Price 3.23 1.40 5.73 90.0% 24.30
12 Cefuroxime Suspension Highest Price # 2.5%
Cefuroxime Suspension Lowest Price 3.16 2.41 3.51 55.0% 4.33
13 Cephalexin Highest Price 5.62 5.54 5.66 32.5% 16.86
Cephalexin Lowest Price 5.40 3.23 5.62 65.0% 16.20
14 Cephalexin Syrup Highest Price 5.53 4.59 5.53 22.5% 2.27
Cephalexin Syrup Lowest Price 4.79 1.55 5.53 50.0% 1.97
15 Ciprofloxacin Brand N.A N.A N.A 0.0% N.A
Ciprofloxacin Highest Price 6.78 6.73 7.28 85.0% 9.27
Ciprofloxacin Lowest Price 3.55 2.40 6.79 100.0% 4.85
16 Co-trimoxazole suspension Brand # 5.0%
Co-trimoxazole suspension Highest Price # 0.0%
Co-trimoxazole suspension Lowest Price 1.29 0.83 1.32 77.5% 0.24
17 Doxycycline Brand 0.0%
Doxycycline Highest Price 9.30 1.80 14.09 55.0% 4.86
Doxycycline Lowest Price 1.82 1.50 14.09 97.5% 0.95
18 Erythromycin powder for
suspension
Highest Price 0.94 0.94 0.94 15.0% 0.50
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Lowest Price 0.94 0.65 0.94 55.0% 0.50
19 Erythromycin Stearate Highest Price 3.48 2.75 3.48 35.0% 4.81
Erythromycin Stearate Lowest Price 2.75 2.03 3.48 82.5% 3.81
20 Gentamicin eye drops Brand # 5.0%
Gentamicin eye drops Highest Price # 2.5%
Gentamicin eye drops Lowest Price 0.97 0.53 1.06 65.0% 1.57
21 Gentamicin injection Highest Price 1.92 1.76 2.15 15.0% 3.83
Gentamicin injection Lowest Price 1.84 1.51 1.96 57.5% 3.66
22 Norfloxacin Highest Price # 5.0%
Norfloxacin Lowest Price 4.72 2.04 4.77 95.0% 4.85
23 Ofloxacin Highest Price 5.22 2.74 5.70 92.5% 8.81
Ofloxacin Lowest Price 2.74 1.48 5.70 97.5% 4.62
24 Roxithromycin Highest Price * 17.5% 7.80
Roxithromycin Lowest Price * 92.5% 7.80
* MSH price is not available therefore MRP cannot be calculated.
# MRP is not calculated if the antibiotic is not available at minimum of 4 outlets.
N.A The brand version of that particular antibiotic is not available in India.
INR Indian Rupees (Local currency).
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cines or therapeutic alternates. Availability data only
refer to the day of data collection at each facility and
might not indicate average availability of medicines over
time. However, since the survey was done in several fa-
cilities over a period of time (2–3 months), the data pro-
vide a reasonable estimate of the overall situation and
are indicative of the real-life situation faced by the pa-
tients on a daily basis. For this survey, data from 68 pub-
lic primary care and 10 public secondary care facilities,









Figure 1 Price variation for a few antibiotics in the highest-priced and
Oflox = Ofloxacin; Doxy = Doxycycline; Ciproflox-Ciprofloxacin; Amoxi + clavthree months. It is only for an individual tertiary care fa-
cility (n = 5) that the availability reported is for one par-
ticular day only. The list of antibiotics surveyed for the
present survey included those commonly used in both
public and private sector as determined from our previ-
ous work on trends of antibiotic used in the community
in Delhi [11] and also the strength and dosage form as
mentioned in the Delhi state EML [18].
It is generally agreed that rapidly increasing antimicro-
bial resistance is due to inappropriate use of antibiotics.




lowest-priced generic available at private retail pharmacies.
= Amoxicillin + clavulanic acid; INR – Indian Rupees (Local currency).
Table 9 Antibiotic unit price in local currency (INR) for
































15.27 (MCD) 14.90 14.90
Imipenem +
cilastin






365.54 (MSO) 1 g inj 1347.00 1347.00
1083.00 (MCD) 1 g inj
1606.50 (CG2) 1 g inj
1662.20 (CG1)
850.50 (CPA) 500 mg;




29.60 (MCD) 69.55 69.55 & 83.60
Vancomycin
500 mg inj
56.70 (MSO) - -
58.80 (CPA & CG1)
64.67 (MCD)
65.45 (CG2)
INR Indian Rupees (Local currency).
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cording to guidelines or non-availability of standard
treatment guidelines, non-availability of appropriate an-
tibiotics, availability of antibiotics without prescription,
inappropriate self-medication and non-adherence to pre-
scribed dosing schedules by patients [22]. We found in
this survey that many newer antibiotics which were not
in the list of Delhi state EML for primary care were
available at primary care facilities of both Delhi govern-
ment (GNCT, Delhi) and MCD run facilities. The survey
revealed that all antibiotics on the list of Delhi state
EML, even those were supposed to be reserve antibiotics
for hospitals like cefuroxime, were available in dispensar-
ies (Primary care facilities) of Delhi government and
MCD. Three antibiotics surveyed, namely, amoxicillin +
clavulanic acid tablet and syrup and cefixime, were notin the Delhi state EML of 2007 (used at the time of the
survey) and we did not get procurement price for them
from CPA-GNCT, Delhi. However, they were all avai-
lable at primary care and secondary care facilities of
GNCT, Delhi and MCD. Although, the revised Delhi
state EML of 2010 [23] has these three antibiotics, pro-
curement at the time of the survey did not use this list
and it would seem that these antibiotics were procured
following some other mechanism. Our earlier surveys
conducted in GNCT, Delhi primary care also found that
newer antibiotics meant for hospital use were available
at primary care and were frequently used by the doctors
[11,12,24]. The present survey also revealed that all anti-
biotics on the Delhi state EML for hospitals, even those
for in-patients, were also available in the dispensaries
(primary care). One procurement officer in CPA depart-
ment of GNCT Delhi stated that all procured antibiotics
are distributed to the dispensaries and that the Delhi
state EML for dispensaries is not used for distribution.
Unfortunately MCD does not have an EML and no sep-
arate lists for primary care, secondary care and tertiary
care facilities.
Unnecessary or inappropriate use of antibiotics must
be curbed immediately. Inappropriate availability will
lead to inappropriate use. The next step is to have the
national or local antibiotic policy including the develop-
ment of an appropriate EML by level of facility, and
monitoring to ensure compliance of procurement and
supply with the EML [25]. Antibiotics should be avail-
able for use at the public sector according to standard
treatment guidelines and the essential medicines list.
Findings of this survey clearly reveal that though the
Delhi state government (GNCT, Delhi) did have an
EML, it was not followed for procurement and distribu-
tion to primary care. The other two agencies, MCD and
facilities of central government had a procurement list
which differed from the Delhi state EML and which may
not have been developed according to patient need. Un-
like a procurement list, development of an EML requires
a committee of expert(s) who clearly understand the
concept and importance of essential medicines and will
prepare and revise the EML including antibiotics on the
basis of essential medicine concepts [26]. Therefore, it is
recommended that all providers should follow the essen-
tial medicine concept and that the EML be adapted to
the differing medicines needs in primary care and ter-
tiary care health care.
It is important to implement the EML and ensure that
procurement and distribution of medicines (antibiotics)
follow the EML according to various level of health care.
None of the antibiotics which were meant for primary
care (dispensaries) had 100% availability or were avail-
able at all the surveyed facilities. Two antibiotics, amoxi-
cillin500 mg and norfloxacin were available between
Table 10 Availability of surveyed high-end antibiotics at
secondary care and tertiary care public facilities and at
private sector facilities






(n = 40) (n = 40)
Cefepime 1 g Inj 20.0% 0.0% 10.0%
Ceftazidime 1 g vial 73.3% 5.0% 20.0%
Colistin 1000000units/vial 0.0% 0.0% 2.5%
Gemifloxacin 320 mg tab/cap 0.0% 37.5% 50.0%
Imipenem + cilastin500mg
+ 500 mg Inj
13.3% 0.0% 22.5%
Meropenem 500 mg Inj 60.0% 32.5% 52.5%
Moxifloxacin 400 mg tab/cap 0.0% 40.0% 72.5%
Vancomycin 500 mg inj 53.3% 5.0% 7.5%
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trimoxazole suspension was available at 71.9% and 56.3%
facilities. Variety of antibiotics was available not ac-
cording to the STGs or EML but according to the supply
in the central store. Availability of antibiotics in se-
condary care hospitals was better than at tertiary care
facilities. This finding indicates probably that smaller
hospitals are managing their store and quantification
better than the tertiary care hospitals in GNCT, Delhi.
Compared to GNCT-run facilities, access to antibi-
otics in MCD-run facilities was poor, none of the sur-
veyed antibiotics having more than 80% availability at
surveyed primary care facilities and only 4 antibiotics
(ciprofloxacin, doxycycline, amoxicillin + clavulanic acid
tablet and syrup) being available in 50% of facilities.
While some essential antibiotics which should be avail-
able at primary care were poorly available, other second
generation antibiotics like ofloxacin, cefuroxime, and
cefixime had better availability than first generation an-
tibiotics at primary care facilities. Availability of anti-
biotics at tertiary care facility was also poor and the
only antibiotic available for children was amoxicillin +
clavulanic acid syrup.
Findings of the survey provide a good baseline and evi-
dence to administrators, managers, and policy makers to
prepare and put in action essential medicine list and a
good antibiotic policy [27]. A committee on EML and
antibiotic policy should ensure that antibiotics are se-
lected, procured, distributed and used more critically
than has been the case up to the present time at differ-
ent level of health care facilities.
For the public sector procurement price of surveyed
antibiotics, it was strange to find that the older off-
patented antibiotics viz., amoxicillin dosage forms and
strength, ampicillin suspension, doxycycline and erythro-
mycin had higher MPR than most of the newer antibi-
otics. This indicates the Indian manufacturers are sellingoff-patented antibiotics at a comparatively higher price
than newer antibiotics. Variation in procurement price
for different agencies was found and for quite a few of
antibiotics, the procurement price of central government
tertiary care facility doing independent procurement was
much higher than other agencies. These findings con-
firm that pooled procurement decreases the procure-
ment price [28,29] and local purchases of medicines
done by individual facility cost higher [30].
At the private sector retail pharmacies, few antibiotics,
like ampicillin suspension and benzathine penicillin
powder for injection were either not available or avail-
able at one or two pharmacies only. This indicates that
these antibiotics are generally not prescribed by doctors.
Newer members from various classes, which are more
expensive than the first generation of antibiotics (e.g.
amoxicillin + clavulanic acid tablet and syrup, cefixime,
cefuroxime, azithromycin, ofloxacin, roxithromycin), were
always available at private pharmacies, as found in our
previous surveys [11]. For a few antibiotics, only one trade
name that is more costly (trade name or branded product)
product was available.
These findings indicate that doctors are prescribing
mainly the branded medicines that are pushed by the
companies through their representatives and that phar-
macists will stock those medicines for which they usually
get prescriptions. In India generic substitution is legally
not allowed. The brand name (trade name) written by a
doctor can not be substituted with another. Some coun-
tries do have generic prescribing policies and/or generic
substitution and such generic policies would be very effi-
cient but it requires a high level of commitment from
government and regulators. Excellent availability of anti-
biotics in the private retail pharmacies and chain phar-
macies may be good news for patients from an access
viewpoint. However, in India, like other developing
countries, antibiotics may be obtained easily from pri-
vate retail pharmacies without a prescription [31], con-
trary to the Indian government regulation and drug
schedules. Indian pharmaceutical GMP guidelines are
given in Drugs and Cosmetics Act 1940. Rules are given
for pharmaceuticals and schedules are there to comply
with the rules. “Schedule H” is a class of prescription
drugs in India under Drugs and Cosmetics rules. Antibi-
otics come under ‘Schedule H’ and legally should not be
dispensed without a prescription.
However, pharmacists themselves prescribe and dis-
pense antibiotics usually for one or two days for condi-
tions like acute diarrhea, sore throat etc. and follows the
prescription of neighborhood practicing doctors [32].
Ministry of Health and Family Welfare, Government of
India has recently prepared National Policy for Contain-
ment of Antimicrobial Resistance-India that covers a
range of actions to be taken including introducing a
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this schedule H1 third generation antibiotics and all
newer antibiotic sales will be restricted [33]. However,
this has yet to be implemented.
In the private sector availability of newer respiratory
fluoroquinolones, gemifloxacin and moxifloxacin was
good. Even meropenam injection was available at 32.5%
retail pharmacies. Availability of these high-end antibi-
otics was better at retail chain pharmacies. Surprisingly,
the retail pharmacies including the chain pharmacies
where these antibiotics were available were not near the
big hospitals but rather in the peri-urban areas or not so
posh areas of Delhi.
Conclusion
Availability of some essential antibiotics is sub-optimal
while other non-essential antibiotics are freely available in
both the public and private sectors. Only one public sector
agency had an EML which was only partially followed in
procurement and distribution. Some newer reserve antibi-
otics are freely available in the private sector and priced
lower than the older essential non-reserve antibiotics.
Such a situation is likely to lead to inappropriate use of an-
tibiotics and contribute to AMR. It is urgent that man-
agerial and regulatory interventions be initiated to ensure
that all public sector procurement follows an EML that
has been developed in an evidence-based manner and that
newer antibiotics are not available OTC in the private sec-
tor at inappropriately low prices.
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